Specific dermatologic features of the polycystic ovary syndrome and its association with biochemical markers of the metabolic syndrome and hyperandrogenism

References

• Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352:1223–36.
   PubMed Web of Science ®Google Scholar
• Guzick DS. Polycystic ovary syndrome [review]. Obstet Gynecol. 2004;103:181–93.
   PubMed Web of Science ®Google Scholar
• Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr Rev. 1999;20:535–82.
   PubMed Web of Science ®Google Scholar
• Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol. 1995;15:821–26.
   PubMed Web of Science ®Google Scholar
• Li L, Yang D, Chen X, Chen Y, Feng S, Wang L. Clinical and metabolic features of polycystic ovary syndrome. Int J Gynaecol Obstet. 2007;97:129–34.
   PubMed Web of Science ®Google Scholar
• Lee AT, Zane LT. Dermatologic manifestations of polycystic ovary syndrome. Am J Clin Dermatol. 2007;8:201–19.
   PubMed Web of Science ®Google Scholar
• The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–25.
   Web of Science ®Google Scholar
• Adams J, Franks S, Polson DW, Mason HD, Abdulwahid N, Tucker M, Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone. Lancet. 1985;2:1375–9.
   PubMed Web of Science ®Google Scholar
• Wijeyaratne CN, Balen AH, Barth JH, Belchetz PE. Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome PCOS) among South Asians and Caucasians: is there a difference? Clin Endocrinol (Oxf). 2002;57:343–50.
   PubMed Web of Science ®Google Scholar
• Hatch R, Rosefield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol. 1981;140:815–30.
   PubMed Web of Science ®Google Scholar
• Braun-Falco O, Plewig G, Wolff HH, Burgdorf WHC. Dermatology, 2nd rev. ed. Berlin: Springer; 2000. pp.1053.
   Google Scholar
• Ozdemir S, Görkemli H, Gezginç K, Ozdemir M, Kiyici A. Clinical and metabolic effects of medroxyprogesterone acetate and ethinyl estradiol plus drospirenone in women with polycystic ovary syndrome. Int J Gynaecol Obstet. 2008;103:44–9.
   PubMed Web of Science ®Google Scholar
• Lowenstein EJ. Diagnosis and management of the dermatologic manifestations of the polycystic ovary syndrome. Dermatol Ther. 2006;19:210–23.
   PubMedGoogle Scholar
• Nelson VL, Qin KN, Rosenfield RL, Wood JR, Penning TM, Legro RS, The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 2001;86:5925–33.
   PubMed Web of Science ®Google Scholar
• Nelson VL, Legro RS, Strauss JF 3rd, McAllister JM. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol. 1999;13:946–57.
   PubMed Web of Science ®Google Scholar
• Falsetti L, Gambera A, Andrico S, Sartori E. Acne and hirsutism in polycystic ovary syndrome: clinical, endocrine-metabolic and ultrasonographic differences. Gynecol Endocrinol. 2002;16:275–84.
   PubMed Web of Science ®Google Scholar
• Ehrmann DA, Liljenquist DR, Azziz R, Kasza K, Legro RS, Ghazzi MN; PCOS/Troglitazone Study Group. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:48–53.
   PubMed Web of Science ®Google Scholar
• Jones GL, Benes K, Clark TL, Denham R, Holder MG, Haynes TJ, The Polycystic Ovary Syndrome Health-Related Quality of Life Questionnaire (PCOSQ): a validation. Hum Reprod. 2004;19:371–7.
   PubMed Web of Science ®Google Scholar
• Chang WY, Knochenhauer ES, Bartolucci AA, Azziz R. Phenotypic spectrum of poycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertil Steril. 2005;83:1717–23.
   PubMed Web of Science ®Google Scholar
• Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab. 2004;89:453–62.
   PubMed Web of Science ®Google Scholar
• Thiboutot D, Gilliland K, Light J, Lookingbill D. Androgen metabolism in sebaceous glands from subjects with without acne. Arch Dermatol. 1999;135:1041–5.
   PubMed Web of Science ®Google Scholar
• Walton S, Cunliffe WJ, Keczkes K, Early AS, McGarrigle HH, Katz M, Clinical, ultrasound and hormonal markers of androgenicity in acne vulgaris. Br J Dermatol. 1995;133:249–53.
   PubMed Web of Science ®Google Scholar
• Borgia F, Cannavò S, Guarneri F, Cannavò SP, Vaccaro M, Guarneri B. Correlation between endocrinological parameters and acne severity in adult women. Acta Derm Venereol. 2004;84:201–4.
   PubMed Web of Science ®Google Scholar
• Cela E, Robertson C, Rush K, Kousta E, White DM, Wilson H, Prevalence of polycystic ovaries in women with androgenic alopecia. Eur J Endocrinol. 2003;49:439–42.
   Google Scholar
• Fraser IS, Kovacs G. Current recommendations for the diagnostic evaluation and follow-up of patients presenting with symptomatic polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004;18:813–23.
   PubMed Web of Science ®Google Scholar
• Cibula D, Hill M, Vohradnikova O, Kuzel D, Fanta M, Zivny J. The role of androgens in determining acne severity in adult women. Br J Dermatol. 2000;143:399–404.
   PubMed Web of Science ®Google Scholar